ETF Holdings Breakdown of IONS

Stock NameIonis Pharmaceuticals Inc
TickerIONS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS4622221004
LEI549300SI4ZGLG0BLUZ92

News associated with IONS

Ionis Pharmaceuticals (NASDAQ:IONS) Shares Gap Up on Better-Than-Expected Earnings
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report)’s stock price gapped up prior to trading on Wednesday following a stronger than expected earnings report. The stock had previously closed at $29.81, but opened at $31.78. Ionis Pharmaceuticals shares last traded at $30.09, with a volume of 185,687 shares trading hands. The company reported ($0.93) EPS […] - 2025-05-02 05:10:54
Mariner LLC Has $967,000 Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Mariner LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 19.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 27,661 shares of the company’s stock after acquiring an additional 4,534 shares during the quarter. Mariner LLC’s holdings in […] - 2025-04-28 08:46:51
Raymond James Financial Inc. Purchases Shares of 105,619 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Raymond James Financial Inc. purchased a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 105,619 shares of the company’s stock, valued at approximately $3,692,000. Raymond James Financial Inc. owned about 0.07% of Ionis Pharmaceuticals […] - 2025-04-28 08:46:49
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Envestnet Asset Management Inc.
Envestnet Asset Management Inc. cut its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 10.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 52,688 shares of the company’s stock after selling 6,126 shares during the period. […] - 2025-04-28 07:37:03
Ionis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) was the target of some unusual options trading on Monday. Stock traders bought 5,610 call options on the company. This is an increase of approximately 1,252% compared to the typical volume of 415 call options. Wall Street Analysts Forecast Growth IONS has been the subject of a […] - 2025-04-23 05:50:51
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Target Price at $56.72
Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have issued a buy rating and […] - 2025-04-21 05:46:52
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Holdings Cut by LPL Financial LLC
LPL Financial LLC lessened its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 5.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 40,376 shares of the company’s stock after selling 2,244 shares during the period. LPL Financial LLC’s holdings in Ionis Pharmaceuticals were worth $1,412,000 as of its most recent […] - 2025-04-18 08:58:49
CIBC Private Wealth Group LLC Sells 1,300 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
CIBC Private Wealth Group LLC reduced its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 53.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,125 shares of the company’s stock after selling 1,300 shares during the quarter. CIBC […] - 2025-04-10 08:15:01
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Strong-Buy at HC Wainwright
HC Wainwright upgraded shares of Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) to a strong-buy rating in a report issued on Monday, Marketbeat reports. The firm currently has $45.00 price target on the stock. A number of other brokerages also recently commented on IONS. Royal Bank of Canada reiterated an “outperform” rating and set a $70.00 […] - 2025-04-10 06:07:15
California Public Employees Retirement System Decreases Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
California Public Employees Retirement System lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 9.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 192,130 shares of the company’s stock after selling 19,626 shares during the period. California Public […] - 2025-04-08 08:22:51
Schroder Investment Management Group Has $3.52 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Schroder Investment Management Group lessened its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 98.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100,659 shares of the company’s stock after selling 4,830,563 shares during the […] - 2025-04-06 08:30:50
Blair William & Co. IL Has $1.39 Million Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Blair William & Co. IL lowered its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 14.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 39,882 shares of the company’s stock after selling 6,769 shares during the period. Blair William & Co. IL’s holdings in Ionis Pharmaceuticals were worth $1,394,000 as of […] - 2025-04-03 08:28:55
Ionis Pharmaceuticals (NASDAQ:IONS) Coverage Initiated at Redburn Atlantic
Research analysts at Redburn Atlantic began coverage on shares of Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) in a report released on Monday, Marketbeat Ratings reports. The brokerage set a “neutral” rating and a $39.00 price target on the stock. Redburn Atlantic’s price objective would suggest a potential upside of 43.07% from the stock’s current […] - 2025-04-02 06:11:00
Vanguard Group Inc. Has $575.88 Million Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Vanguard Group Inc. increased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 9.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,472,539 shares of the company’s stock after purchasing an additional 1,416,781 shares during the quarter. Vanguard […] - 2025-04-01 08:27:05
KLP Kapitalforvaltning AS Acquires Shares of 29,200 Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
KLP Kapitalforvaltning AS bought a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 29,200 shares of the company’s stock, valued at approximately $1,021,000. Other large investors also recently modified their holdings […] - 2025-03-31 07:56:52
Natixis Advisors LLC Sells 6,767 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Natixis Advisors LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 32.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 14,313 shares of the company’s stock after selling 6,767 shares during the quarter. Natixis Advisors LLC’s holdings in Ionis Pharmaceuticals were worth $500,000 at the end of […] - 2025-03-28 08:38:50
Brokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $59.56
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty research firms that are covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, thirteen have given a buy recommendation and one has issued […] - 2025-03-27 05:48:54
Xponance Inc. Acquires 318 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Xponance Inc. increased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,339 shares of the company’s stock after purchasing an additional 318 shares during the period. Xponance Inc.’s […] - 2025-03-26 08:34:58
Signaturefd LLC Purchases 584 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Signaturefd LLC lifted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 160.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 949 shares of the company’s stock after purchasing an additional 584 shares during the period. Signaturefd […] - 2025-03-26 07:48:47
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Cut to $45.00 by Analysts at JPMorgan Chase & Co.
Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price objective lowered by JPMorgan Chase & Co. from $47.00 to $45.00 in a research report released on Monday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the stock. A number of other research firms also recently issued reports on IONS. StockNews.com raised Ionis […] - 2025-03-25 05:55:00
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Sell at StockNews.com
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a research note issued to investors on Tuesday. Several other analysts have also issued reports on the company. JPMorgan Chase & Co. lowered their target price on Ionis Pharmaceuticals from $51.00 to $47.00 and set a “neutral” […] - 2025-03-20 05:44:55
Arizona State Retirement System Has $1.44 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Arizona State Retirement System raised its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 8.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,147 shares of the company’s stock after acquiring an additional 3,320 shares during the quarter. […] - 2025-03-13 08:48:49
Jones Financial Companies Lllp Acquires 2,614 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Jones Financial Companies Lllp boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 38.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,338 shares of the company’s stock after buying an additional 2,614 shares during the period. Jones Financial Companies […] - 2025-03-12 08:03:05
Principal Financial Group Inc. Has $476,000 Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Principal Financial Group Inc. increased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 3.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 13,616 shares of the company’s stock after acquiring an additional 504 shares during the quarter. Principal Financial Group Inc.’s holdings in Ionis Pharmaceuticals were worth $476,000 at the […] - 2025-03-07 08:16:55
Amalgamated Bank Acquires 335 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Amalgamated Bank lifted its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,292 shares of the company’s stock after acquiring an additional 335 shares during the period. Amalgamated Bank’s […] - 2025-03-05 10:26:53
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lessened its stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 53.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,407 shares of the company’s stock after selling 10,734 shares during the period. Y Intercept Hong Kong […] - 2025-03-04 08:28:56
Van ECK Associates Corp Raises Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Van ECK Associates Corp raised its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 4.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 61,619 shares of the company’s stock after buying an additional 2,613 shares during the quarter. Van ECK Associates Corp’s holdings in Ionis Pharmaceuticals were worth $2,154,000 as […] - 2025-02-21 08:16:55
Ionis Pharma Beats Expectations for Q4
Ionis Pharmaceuticals (NASDAQ:IONS), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the - 2025-02-19 18:26:55
Sumitomo Mitsui Trust Group Inc. Decreases Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Sumitomo Mitsui Trust Group Inc. lessened its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 20.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 156,657 shares of the company’s stock after selling 39,457 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Ionis Pharmaceuticals were worth $5,477,000 as of […] - 2025-02-14 09:01:06
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stake Lessened by DAVENPORT & Co LLC
DAVENPORT & Co LLC lowered its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 17.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 62,740 shares of the company’s stock after selling 12,858 shares during the period. DAVENPORT & Co LLC’s holdings in Ionis Pharmaceuticals were worth $2,193,000 as of its most […] - 2025-02-05 08:54:56

IONS institutional holdings

The following institutional investment holdings of IONS have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 86,580USD 2,835,495
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 14,659USD 480,082 -1.0%
2025-05-08 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 186,219USD 6,098,672 -1.0%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 75,699USD 2,479,142
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 75,699USD 2,479,142 -1.0%
2025-05-08 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 1,655USD 54,201 -1.0%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 288USD 9,432 -1.0%
2025-05-08 IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc)) 1,699USD 55,642 -1.0%
2025-02-03 IE000WHL2ZK1 (iShares U.S. Equity High Income UCITS ETF USD Inc) 219USD 7,036 0.7%
2025-05-08 IE000D8XC064 (iShares World Equity Enhanced Active UCITS ETF USD (Acc)) 2,769USD 90,685 -1.0%
Total =445,486 USD 14,589,529
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.